Status:
COMPLETED
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Relapsing-Remitting Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study on the extent to which subject compliance is influenced by use of a variable titration regimen at the start o...
Detailed Description
Interferon beta has become the treatment of choice in relapsing MS. In previous clinical studies, the interferon-beta 1a (Rebif) used within the scope of this PMS study has demonstrated significant ef...
Eligibility Criteria
Inclusion
- Subjects with clinically diagnosed multiple sclerosis (MS) and relapses
Exclusion
- Subjects with secondary progressive MS (SPMS) without relapses, pregnant or breastfeeding subjects, and subjects with contra- indications.
- Subjects with systemic concomitant diseases (e.g. diabetes, heart disease, liver disease, or renal disease)
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
403 Patients enrolled
Trial Details
Trial ID
NCT01142492
Start Date
January 1 2005
End Date
July 1 2008
Last Update
March 18 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.